Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BIXT NYSE:CLDI OTCMKTS:NSPX NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIXTBioxytran$0.08+1.3%$0.09$0.06▼$0.23$6.85M1.93119,805 shs34,738 shsCLDICalidi Biotherapeutics$1.60+1.9%$5.04$1.51▼$46.68$5.48M1.08637,444 shs244,892 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsSXTP60 Degrees Pharmaceuticals$1.41-4.7%$1.59$1.22▼$12.45$6.07M2.7386,967 shs41,708 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIXTBioxytran+1.30%+20.37%-4.76%-42.22%-13.14%CLDICalidi Biotherapeutics+1.91%-3.03%-74.11%-62.55%-88.41%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%SXTP60 Degrees Pharmaceuticals-4.73%0.00%+4.83%-51.71%-79.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIXTBioxytran$0.08+1.3%$0.09$0.06▼$0.23$6.85M1.93119,805 shs34,738 shsCLDICalidi Biotherapeutics$1.60+1.9%$5.04$1.51▼$46.68$5.48M1.08637,444 shs244,892 shsNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsSXTP60 Degrees Pharmaceuticals$1.41-4.7%$1.59$1.22▼$12.45$6.07M2.7386,967 shs41,708 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIXTBioxytran+1.30%+20.37%-4.76%-42.22%-13.14%CLDICalidi Biotherapeutics+1.91%-3.03%-74.11%-62.55%-88.41%NSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%SXTP60 Degrees Pharmaceuticals-4.73%0.00%+4.83%-51.71%-79.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIXTBioxytran 0.00N/AN/AN/ACLDICalidi Biotherapeutics 0.00N/AN/AN/ANSPXInspyr Therapeutics 0.00N/AN/AN/ASXTP60 Degrees Pharmaceuticals 2.50Moderate Buy$3.00112.77% UpsideCurrent Analyst Ratings BreakdownLatest NSPX, SXTP, BIXT, and CLDI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025SXTP60 Degrees PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $3.008/30/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/29/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/12/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating6/27/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating6/11/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIXTBioxytranN/AN/AN/AN/A($0.02) per shareN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/A($2.32) per shareN/ANSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ASXTP60 Degrees Pharmaceuticals$300K19.27N/AN/A($6.38) per share-0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIXTBioxytran-$2.37M-$0.03N/A∞N/AN/AN/A-1,577.96%N/ACLDICalidi Biotherapeutics-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/ANSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/ASXTP60 Degrees Pharmaceuticals-$7.95M-$50.41N/AN/AN/A-976.86%N/A-133.88%11/13/2025 (Estimated)Latest NSPX, SXTP, BIXT, and CLDI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SXTP60 Degrees Pharmaceuticals-$1.24-$1.25-$0.01-$1.25$0.32 million$0.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIXTBioxytranN/AN/AN/AN/AN/ACLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ANSPXInspyr TherapeuticsN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIXTBioxytranN/AN/AN/ACLDICalidi BiotherapeuticsN/A0.190.19NSPXInspyr TherapeuticsN/A0.090.09SXTP60 Degrees PharmaceuticalsN/A2.271.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIXTBioxytranN/ACLDICalidi Biotherapeutics12.53%NSPXInspyr Therapeutics0.02%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipBIXTBioxytran70.00%CLDICalidi Biotherapeutics6.70%NSPXInspyr Therapeutics0.02%SXTP60 Degrees Pharmaceuticals1.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIXTBioxytran288.99 million26.70 millionNot OptionableCLDICalidi Biotherapeutics383.43 million20.04 millionN/ANSPXInspyr Therapeutics1543.15 millionN/ANot OptionableSXTP60 Degrees Pharmaceuticals34.10 million4.04 millionNot OptionableNSPX, SXTP, BIXT, and CLDI HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3 at 8:02 AM | globenewswire.com60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given Sell (E+) Rating at Weiss RatingsAugust 31, 2025 | americanbankingnews.com60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 21, 2025 | globenewswire.com60 Degrees selects Icahn School of Medicine as central site for Phase II studyAugust 19, 2025 | msn.com60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisAugust 19, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces Second Quarter 2025 ResultsAugust 13, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public OfferingJuly 16, 2025 | globenewswire.com60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration ...July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public OfferingJuly 15, 2025 | globenewswire.com60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 BillionJuly 15, 2025 | globenewswire.comSXTP - 60 Degrees Pharmaceuticals Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comM60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 SharesJune 6, 2025 | insidertrades.com60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026June 5, 2025 | nasdaq.com60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle FormatJune 4, 2025 | globenewswire.comBabesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees PharmaceuticalsJune 3, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsMay 15, 2025 | globenewswire.comBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyApril 22, 2025 | globenewswire.comWhy 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?April 10, 2025 | insidermonkey.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPX, SXTP, BIXT, and CLDI Company DescriptionsBioxytran OTCMKTS:BIXT$0.08 +0.00 (+1.30%) As of 09/5/2025 02:47 PM EasternBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.Calidi Biotherapeutics NYSE:CLDI$1.60 +0.03 (+1.91%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Inspyr Therapeutics OTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.41 -0.07 (-4.73%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.35 -0.06 (-4.54%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
